Maze Therapeutics completes routine annual meeting, elects two directors for three-year terms

Filed June 10, 2026 · Period ending June 8, 2026 · ~1 min read

Key Changes

• low

  Stockholders elected Jason Coloma, Ph.D. and Neil Kumar, Ph.D. as Class I directors to serve until 2029. Both received majority support, with Coloma getting 86% approval and Kumar 82%.

  Item 5.07 verify on EDGAR →
• low

  Ernst & Young LLP ratified as independent auditor for 2026 with near-unanimous approval (99.8% of votes cast in favor).

  Item 5.07 verify on EDGAR →